Provided by Tiger Fintech (Singapore) Pte. Ltd.

Rani Therapeutics Holdings

1.21
-0.0900-6.92%
Post-market: 1.210.00000.00%18:41 EDT
Volume:184.85K
Turnover:225.84K
Market Cap:40.31M
PE:-1.15
High:1.27
Open:1.25
Low:1.17
Close:1.30
Loading ...

Rani Therapeutics Price Target Maintained With a $9.00/Share by HC Wainwright & Co.

Dow Jones
·
03 Apr

Rani Therapeutics Holdings: Buy Rating Backed by Strong Financial Position and Promising Clinical Trials

TIPRANKS
·
03 Apr

RANI: 2024 Financial Results

Zacks Small Cap Research
·
01 Apr

Stifel Nicolaus Reaffirms Their Buy Rating on Rani Therapeutics Holdings (RANI)

TIPRANKS
·
01 Apr

Rani Therapeutics Holdings Inc (RANI) Q4 2024 Earnings Call Highlights: Navigating Financial ...

GuruFocus.com
·
01 Apr

BRIEF-Rani Therapeutics Q4 Operating Expenses USD 15.986 Million

Reuters
·
01 Apr

Rani Therapeutics Holdings Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
01 Apr

Rani Therapeutics Hldgs Q4 2024 GAAP EPS $(0.27) Misses $(0.25) Estimate

Benzinga
·
01 Apr

Rani Therapeutics Q4 Operating Expenses USD 15.986 Million

THOMSON REUTERS
·
01 Apr

Rani Therapeutics Holdings Inc Q4 Shr View $-0.25 -- Lseg Ibes Data

THOMSON REUTERS
·
01 Apr

Rani Therapeutics Holdings Inc Q4 Shr Loss $0.27

THOMSON REUTERS
·
01 Apr

Rani Therapeutics Holdings: Cash, Cash Equivalents & Marketable Securities Sufficient to Fund Ops Into Q3

THOMSON REUTERS
·
01 Apr

Press Release: Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update

Dow Jones
·
01 Apr

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
31 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
27 Mar

BRIEF-Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence Of RT-114, A GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally Via The RaniPill Capsule, To Subcutaneously Administered PG-102

Reuters
·
27 Mar

Rani Therapeutics Holdings Inc expected to post a loss of 25 cents a share - Earnings Preview

Reuters
·
27 Mar

Rani Therapeutics Holdings: Phase 1 Clinical Study for Rt-114 for Treatment of Obesity Expected to Initiate in Mid- 2025

THOMSON REUTERS
·
27 Mar

Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of Rt-114, a Glp-1/Glp-2 Dual Agonist (Pg-102) Delivered Orally via the Ranipill® Capsule, to Subcutaneously Administered Pg-102

THOMSON REUTERS
·
27 Mar

Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102

GlobeNewswire
·
27 Mar